{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:22:57Z","timestamp":1774581777862,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BD\/131468\/2017"],"award-info":[{"award-number":["SFRH\/BD\/131468\/2017"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["LA\/P\/0059\/2020-AL4AnimalS"],"award-info":[{"award-number":["LA\/P\/0059\/2020-AL4AnimalS"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["LA\/P\/0059\/2020-AL4AnimalS"],"award-info":[{"award-number":["LA\/P\/0059\/2020-AL4AnimalS"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["LA\/P\/0059\/2020-AL4AnimalS"],"award-info":[{"award-number":["LA\/P\/0059\/2020-AL4AnimalS"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SAICT\/2017\/32085"],"award-info":[{"award-number":["SAICT\/2017\/32085"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antibody\u2013drug conjugates (ADCs) are among the fastest-growing classes of therapeutics in oncology. Although ADCs are in the spotlight, they still present significant engineering challenges. Therefore, there is an urgent need to develop more stable and effective ADCs. Most rabbit light chains have an extra disulfide bridge, that links the variable and constant domains, between Cys80 and Cys171, which is not found in the human or mouse. Thus, to develop a new generation of ADCs, we explored the potential of rabbit-derived VL-single-domain antibody scaffolds (sdAbs) to selectively conjugate a payload to Cys80. Hence, a rabbit sdAb library directed towards canine non-Hodgkin lymphoma (cNHL) was subjected to in vitro and in vivo phage display. This allowed the identification of several highly specific VL-sdAbs, including C5, which specifically target cNHL cells in vitro and present promising in vivo tumor uptake. C5 was selected for SN-38 site-selective payload conjugation through its exposed free Cys80 to generate a stable and homogenous C5-DAB-SN-38. C5-DAB-SN-38 exhibited potent cytotoxicity activity against cNHL cells while inhibiting DNA-TopoI activity. Overall, our strategy validates a platform to develop a novel class of ADCs that combines the benefits of rabbit VL-sdAb scaffolds and the canine lymphoma model as a powerful framework for clinically translation of novel therapeutics for cancer.\n<\/jats:p>","DOI":"10.1038\/s41598-023-31568-x","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T10:03:44Z","timestamp":1679652224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rabbit derived VL single-domains as promising scaffolds to generate antibody\u2013drug conjugates"],"prefix":"10.1038","volume":"13","author":[{"given":"Ana S.","family":"Andr\u00e9","sequence":"first","affiliation":[]},{"given":"Joana N. R.","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Aguiar","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Nogueira","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Bule","sequence":"additional","affiliation":[]},{"given":"Joana In\u00eas","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o P. M.","family":"Ant\u00f3nio","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Cavaco","sequence":"additional","affiliation":[]},{"given":"Vera","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Soraia","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo","family":"Vicente","sequence":"additional","affiliation":[]},{"given":"Belmira","family":"Carrapi\u00e7o","sequence":"additional","affiliation":[]},{"given":"Berta S\u00e3o","family":"Braz","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"R\u00fctgen","sequence":"additional","affiliation":[]},{"given":"Lurdes","family":"Gano","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o D. G.","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Castanho","sequence":"additional","affiliation":[]},{"given":"Joao","family":"Goncalves","sequence":"additional","affiliation":[]},{"given":"Pedro M. P.","family":"Gois","sequence":"additional","affiliation":[]},{"given":"Solange","family":"Gil","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Frederico","family":"Aires-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"31568_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2016","unstructured":"Carter, P. J. Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019. Nat. Rev. Drug Discov. 17, 197\u2013223 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31568_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"31568_CR3","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita","year":"2008","unstructured":"DeVita, V. T. & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643\u20138653 (2008).","journal-title":"Cancer Res."},{"key":"31568_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","volume":"15","author":"GJ Weiner","year":"2015","unstructured":"Weiner, G. J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15, 361\u2013370 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"31568_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","volume":"64","author":"EL Sievers","year":"2013","unstructured":"Sievers, E. L. & Senter, P. D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15\u201329 (2013).","journal-title":"Annu. Rev. Med."},{"key":"31568_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/ph13090245","volume":"13","author":"N Joubert","year":"2020","unstructured":"Joubert, N., Beck, A., Dumontet, C. & Denevault-Sabourin, C. Antibody-drug conjugates: The last decade. Pharmaceuticals 13, 345 (2020).","journal-title":"Pharmaceuticals"},{"key":"31568_CR7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1248\/cpb.c21-00258","volume":"69","author":"Y Matsuda","year":"2021","unstructured":"Matsuda, Y. & Mendelsohn, B. A. Recent advances in drug-antibody ratio determination of antibody-drug conjugates. Chem. Pharm. Bull. (Tokyo) 69, 976\u2013983 (2021).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"31568_CR8","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1110\/ps.051478705","volume":"14","author":"L Wang","year":"2005","unstructured":"Wang, L., Amphlett, G., Bl\u00e4ttler, W. A., Lambert, J. M. & Zhang, W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Prot. Sci. 14, 2436\u20132446 (2005).","journal-title":"Prot. Sci."},{"key":"31568_CR9","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett, K. J. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063\u20137070 (2004).","journal-title":"Clin. Cancer Res."},{"key":"31568_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","volume":"30","author":"B-Q Shen","year":"2012","unstructured":"Shen, B.-Q. et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30, 184\u2013189 (2012).","journal-title":"Nat. Biotechnol."},{"key":"31568_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2014","unstructured":"Panowski, S., Bhakta, S., Raab, H., Polakis, P. & Junutula, J. R. Site-specific antibody drug conjugates for cancer therapy. MAbs 6, 34\u201345 (2014).","journal-title":"MAbs"},{"key":"31568_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corva\u00efa, N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat. Rev. Drug Discovery 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"31568_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fphar.2019.00373","volume":"10","author":"H Tang","year":"2019","unstructured":"Tang, H. et al. The analysis of key factors related to ADCs structural design. Front. Pharmacol. 10, 373 (2019).","journal-title":"Front. Pharmacol."},{"key":"31568_CR14","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1021\/acs.bioconjchem.0c00337","volume":"31","author":"RGE Coumans","year":"2020","unstructured":"Coumans, R. G. E. et al. A platform for the generation of site-specific antibody-drug conjugates that allows for selective reduction of engineered cysteines. Bioconjugate Chem. 31, 2136\u20132146 (2020).","journal-title":"Bioconjugate Chem."},{"key":"31568_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1021\/acs.bioconjchem.1c00246","volume":"32","author":"M Boschanski","year":"2021","unstructured":"Boschanski, M. et al. Site-specific conjugation strategy for dual antibody-drug conjugates using aerobic formylglycine-generating enzymes. Bioconjugate Chem. 32, 1167\u20131174 (2021).","journal-title":"Bioconjugate Chem."},{"key":"31568_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/ph14070672","volume":"14","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q. et al. Site-specific antibody conjugation to engineered double cysteine residues. Pharmaceuticals 14, 672 (2021).","journal-title":"Pharmaceuticals"},{"key":"31568_CR17","first-page":"1","volume":"17","author":"EG Kim","year":"2015","unstructured":"Kim, E. G. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomol. Ther. 17, 1 (2015).","journal-title":"Biomol. Ther."},{"key":"31568_CR18","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-15-0480","volume":"14","author":"R G\u00e9bleux","year":"2015","unstructured":"G\u00e9bleux, R., Wulhfard, S., Casi, G. & Neri, D. Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody-drug conjugates. Mol. Cancer Ther. 14, 2606\u20132612 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"31568_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/pharmaceutics14081524","volume":"14","author":"L Jolivet","year":"2022","unstructured":"Jolivet, L. et al. Intra-domain cysteines (IDC), a new strategy for the development of original antibody fragment-drug conjugates (FDCs). Pharmaceutics 14, 1524 (2022).","journal-title":"Pharmaceutics"},{"key":"31568_CR20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","volume":"80","author":"I Nessler","year":"2020","unstructured":"Nessler, I. et al. Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Res. 80, 1268\u20131278 (2020).","journal-title":"Cancer Res."},{"key":"31568_CR21","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12967-020-02538-y","volume":"18","author":"T Chen","year":"2020","unstructured":"Chen, T., Liu, X., Hong, H. & Wei, H. Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect. J. Transl. Med. 18, 376 (2020).","journal-title":"J. Transl. Med."},{"key":"31568_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fimmu.2018.00273","volume":"9","author":"ME Iezzi","year":"2018","unstructured":"Iezzi, M. E., Policastro, L., Werbajh, S., Podhajcer, O. & Canziani, G. A. Single-domain antibodies and the promise of modular targeting in cancer imaging and treatment. Front. Immunol. 9, 273 (2018).","journal-title":"Front. Immunol."},{"key":"31568_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2165\/00063030-200822050-00003","volume":"22","author":"F Aires da Silva","year":"2008","unstructured":"Aires da Silva, F., Corte-Real, S. & Goncalves, J. Recombinant antibodies as therapeutic agents: Pathways for modeling new biodrugs. BioDrugs 22, 301\u2013314 (2008).","journal-title":"BioDrugs"},{"key":"31568_CR24","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/pharmaceutics13101598","volume":"13","author":"SI Aguiar","year":"2021","unstructured":"Aguiar, S. I. et al. Highly specific blood-brain barrier transmigrating single-domain antibodies selected by an in vivo phage display screening. Pharmaceutics 13, 1598 (2021).","journal-title":"Pharmaceutics"},{"key":"31568_CR25","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1038\/s41598-022-06549-1","volume":"12","author":"JNR Dias","year":"2022","unstructured":"Dias, J. N. R. et al. Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy. Sci. Rep. 12, 2678 (2022).","journal-title":"Sci. Rep."},{"key":"31568_CR26","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1111\/febs.14192","volume":"284","author":"Z Gouveia","year":"2017","unstructured":"Gouveia, Z. et al. Characterization of plasma labile heme in hemolytic conditions. FEBS J. 284, 3278\u20133301 (2017).","journal-title":"FEBS J."},{"key":"31568_CR27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1097\/QAD.0000000000001108","volume":"30","author":"C Cunha-Santos","year":"2016","unstructured":"Cunha-Santos, C. et al. Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. AIDS 30, 1691\u20131701 (2016).","journal-title":"AIDS"},{"key":"31568_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jmb.2004.04.062","volume":"340","author":"FA da Silva","year":"2004","unstructured":"da Silva, F. A. et al. Camelized Rabbit-derived VH Single-domain Intrabodies Against Vif Strongly Neutralize HIV-1 Infectivity. J. Mol. Biol. 340, 525\u2013542 (2004).","journal-title":"J. Mol. Biol."},{"key":"31568_CR29","unstructured":"Braz Gon\u00e7alves, J. & Silva, F. A. da. Engineered rabbit antibody variable domains and uses thereof. Patent application No. PCT\/PT2008\/000018; WO2008136694A9 (2008)."},{"key":"31568_CR30","unstructured":"Aires-Da-Silva, F., C\u00f4rte-Real, S., Freitas, R. & Louren\u00e7o, S. Anti-tumor necrosis factor-alpha agents and uses thereof. Patent application No. PCT\/PT2012\/000035; WO2013043070A9 (2012)."},{"key":"31568_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0022-2836(02)01232-9","volume":"325","author":"M Popkov","year":"2003","unstructured":"Popkov, M. et al. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: The impact of Kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J. Mol. Biol. 325, 325\u2013335 (2003).","journal-title":"J. Mol. Biol."},{"key":"31568_CR32","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1073\/pnas.81.6.1794","volume":"81","author":"N McCartney-Francis","year":"1984","unstructured":"McCartney-Francis, N., Skurla, R. M., Mage, R. G. & Bernstein, K. E. Kappa-chain allotypes and isotypes in the rabbit: cDNA sequences of clones encoding b9 suggest an evolutionary pathway and possible role of the interdomain disulfide bond in quantitative allotype expression. Proc. Natl. Acad. Sci. USA 81, 1794\u20131798 (1984).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"31568_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/emm.2017.23","volume":"49","author":"J Weber","year":"2017","unstructured":"Weber, J., Peng, H. & Rader, C. From rabbit antibody repertoires to rabbit monoclonal antibodies. Exp. Mol. Med. 49, 305 (2017).","journal-title":"Exp. Mol. Med."},{"key":"31568_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2019.109940","volume":"218","author":"JNR Dias","year":"2019","unstructured":"Dias, J. N. R. et al. Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation. Vet. Immunol. Immunopathol. 218, 109940 (2019).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"31568_CR35","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","volume":"34","author":"BC R\u00fctgen","year":"2010","unstructured":"R\u00fctgen, B. C. et al. Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk. Res. 34, 932\u2013938 (2010).","journal-title":"Leuk. Res."},{"key":"31568_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040078","volume":"7","author":"BC R\u00fctgen","year":"2012","unstructured":"R\u00fctgen, B. C. et al. Authentication of Primordial Characteristics of the CLBL-1 Cell Line Prove the Integrity of a Canine B-Cell Lymphoma in a Murine In Vivo Model. PLoS ONE 7, e40078 (2012).","journal-title":"PLoS ONE"},{"key":"31568_CR37","unstructured":"Barbas III, C. F., Burton, D. R., Scott, J. K. & Silverman, G. J. Phage Display: A Laboratory Manual. (Cold Spring Harbor Laboratory Press, 2001)."},{"key":"31568_CR38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jim.2004.05.004","volume":"291","author":"M Popkov","year":"2004","unstructured":"Popkov, M., Rader, C. & Barbas, C. F. Isolation of human prostate cancer cell reactive antibodies using phage display technology. J. Immunol. Methods 291, 137\u2013151 (2004).","journal-title":"J. Immunol. Methods"},{"key":"31568_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208147","volume":"13","author":"JNR Dias","year":"2018","unstructured":"Dias, J. N. R. et al. Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies. PLoS ONE 13, e0208147 (2018).","journal-title":"PLoS ONE"},{"key":"31568_CR40","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.3390\/molecules26195847","volume":"26","author":"JTW Tong","year":"2021","unstructured":"Tong, J. T. W., Harris, P. W. R., Brimble, M. A. & Kavianinia, I. An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules 26, 5847 (2021).","journal-title":"Molecules"},{"key":"31568_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40425-016-0200-7","volume":"4","author":"JS Park","year":"2016","unstructured":"Park, J. S. et al. Canine cancer immunotherapy studies: Linking mouse and human. J. Immunother Cancer 4, 97 (2016).","journal-title":"J. Immunother Cancer"},{"key":"31568_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hon.2017","volume":"31","author":"L Marconato","year":"2013","unstructured":"Marconato, L., Gelain, M. E. & Comazzi, S. The dog as a possible animal model for human non-Hodgkin lymphoma: A review: The dog as model for human non-Hodgkin lymphoma. Hematol. Oncol. 31, 1\u20139 (2013).","journal-title":"Hematol. Oncol."},{"key":"31568_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2021.621758","volume":"8","author":"JNR Dias","year":"2021","unstructured":"Dias, J. N. R. et al. Immunotherapeutic strategies for canine lymphoma: Changing the odds against non-hodgkin lymphoma. Front. Vet. Sci. 8, 621758 (2021).","journal-title":"Front. Vet. Sci."},{"key":"31568_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.addr.2018.06.015","volume":"130","author":"HH Gustafson","year":"2018","unstructured":"Gustafson, H. H., Olshefsky, A., Sylvestre, M., Sellers, D. L. & Pun, S. H. Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting. Adv. Drug Deliv. Rev. 130, 39\u201349 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"31568_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2022.962124","volume":"13","author":"AS Andr\u00e9","year":"2022","unstructured":"Andr\u00e9, A. S., Moutinho, I., Dias, J. N. R. & Aires-da-Silva, F. In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties. Front. Microbiol. 13, 1 (2022).","journal-title":"Front. Microbiol."},{"key":"31568_CR46","first-page":"561","volume":"4","author":"M Soendergaard","year":"2014","unstructured":"Soendergaard, M., Newton-Northup, J. R. & Deutscher, S. L. In vivo phage display selection of an ovarian cancer targeting peptide for SPECT\/CT imaging. Am. J. Nucl. Med. Mol. Imaging 4, 561\u2013570 (2014).","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"31568_CR47","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/molecules16010900","volume":"16","author":"AN Veleva","year":"2011","unstructured":"Veleva, A. N. et al. Efficient In Vivo Selection of a Novel Tumor-Associated Peptide from a Phage Display Library. Molecules 16, 900\u2013914 (2011).","journal-title":"Molecules"},{"key":"31568_CR48","unstructured":"Schneider, D. W. et al. In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin\/RG-1, Engineered Antibody Fragments in LNCaP Tumor\u2013Bearing Nude Mice. 9."},{"key":"31568_CR49","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13045-021-01171-6","volume":"14","author":"E Duray","year":"2021","unstructured":"Duray, E. et al. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. J. Hematol. Oncol. 14, 183 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"31568_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-016-0335-x","volume":"35","author":"NF Jensen","year":"2016","unstructured":"Jensen, N. F. et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. J. Exp. Clin. Cancer Res. 35, 56 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"31568_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1021\/cb300648v","volume":"8","author":"Y Pommier","year":"2013","unstructured":"Pommier, Y. Drugging topoisomerases: Lessons and challenges. ACS Chem. Biol. 8, 82\u201395 (2013).","journal-title":"ACS Chem. Biol."},{"key":"31568_CR52","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","volume":"30","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol. Ther. 30, 2785\u20132799 (2022).","journal-title":"Mol. Ther."},{"key":"31568_CR53","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed, Y. Y. Sacituzumab govitecan: First approval. Drugs 80, 1019\u20131025 (2020).","journal-title":"Drugs"},{"key":"31568_CR54","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12, 931\u2013947 (2013).","journal-title":"Nat Rev Drug Discov"},{"key":"31568_CR55","doi-asserted-by":"publisher","first-page":"25914","DOI":"10.1002\/anie.202109835","volume":"60","author":"JPM Ant\u00f3nio","year":"2021","unstructured":"Ant\u00f3nio, J. P. M. et al. Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates**. Angew. Chem. Int. Ed. 60, 25914\u201325921 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"31568_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/oncotarget.25580","volume":"9","author":"JNR Dias","year":"2018","unstructured":"Dias, J. N. R. et al. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget 9, 1 (2018).","journal-title":"Oncotarget"},{"key":"31568_CR57","unstructured":"Kabat, E. A., Wu, T. T., Perry, H. M., Foeller, C. & Gottesman, K. S. Sequences of Proteins of Immunological Interest. (NIH publication, 1991)."},{"key":"31568_CR58","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nprot.2015.053","volume":"10","author":"LA Kelley","year":"2015","unstructured":"Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. E. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10, 845\u2013858 (2015).","journal-title":"Nat. Protoc."},{"key":"31568_CR59","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31568-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T11:13:38Z","timestamp":1679656418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31568-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31568"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31568-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to disclose that: FAS, ASA, JD, SIA, SO, LT, JIC, JA and PG have pending patent applications related to the development of ADCs from rabbit derived single-domain antibodies (PCT\/IB2022\/056303) and ROS-linker sensitive diazaborines (Application number: 20211000023853). All other authors have no competing\/conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4837"}}